Dr Steve Hood and Dr Richard Kirsh
Starts: 14 May 2014
Wednesday 14th May 2014
GSK, UK and USA
The Challenges of Transforming Oligonucleotides from Research Molecules into Reimbursable Medicines
Steve Hood PhD
Steve studied for his PhD in Molecular Toxicology at Surrey University and joined Glaxo Group Research as a Post-Doctoral fellow in 1993 where he produced recombinant drug metabolising enzymes for the DMPK department.
Following the formation of GSK in 2001, Steve managed a team determining the Drug-Drug interaction liabilities of co-medicated drugs while developing ADME strategies for the emerging GSK antibody portfolio.
In 2010, Steve joined a cross divisional team charged with understanding and overcoming of the delivery issues inherent in GSK’s diverse oligonucleotide portfolio. Steve is currently the Director of the GSK Oligonucleotide Delivery (GOLD) team and Co-coordinator of the IMI COMPACT project, a European Consortium that includes researchers from the Cardiff School of Pharmacy and Pharmaceutical Sciences and the School of Biosciences Cardiff University .
Paul Spencer Lecture Theatre, Redwood (2.60C)
Refreshments from 1:20pm
Open To: Public
Staff and Students